Health Secretary Wes Streeting has indicated a willingness to endorse a national prostate cancer screening program targeted at men identified as being at higher risk of the disease, contingent upon a robust evidence base supporting such a measure.

His comments were made during a session with the House of Commons’ Health and Social Care Committee, where he underscored the importance of evidence-led policymaking in the health sector.

Currently, the UK’s National Screening Committee is scrutinizing whether a national screening initiative should be implemented.

The prostate-specific antigen (PSA) test, a blood examination utilized to detect prostate issues, including cancer and enlarged prostate, is not routinely available through the National Health Service (NHS).

However, general practitioners (GPs) may recommend the test to patients if prostate cancer is suspected, and men over the age of 50 have the option to request a PSA test even in the absence of symptoms.

There has been a growing demand for the introduction of routine PSA testing across the NHS, but concerns have also been raised regarding the potential for overdiagnosis and unnecessary treatment resulting from widespread testing.

This sentiment reflects a broader debate in the medical community regarding the balance between proactive healthcare measures and the implications of aggressive screening practices.

During his remarks, Streeting acknowledged the complexity of the issue, stating, “I would like to see that.

But, and this is such an important but, decisions in this area do need to be evidence-based and evidence-led.” He highlighted the necessity of drawing upon empirical data to dictate healthcare policies, rather than yielding to public pressure or popular campaigns.

Despite his openness to the idea of a screening program, he reiterated that the commitment to resource allocation must be informed by strong evidence.

Streeting also emphasized the importance of increasing public awareness around prostate cancer, saying, “This is a really important campaign on a couple of fronts: firstly, awareness is really important… making sure that people do go and get checked is important.” He called for open discussions about prostate health, paralleling the need for communication around other health issues, such as breast cancer.

In response to the ongoing deliberations, Prostate Cancer UK has advocated for an update to medical guidelines, enabling GPs to engage in proactive discussions about testing with men classified as high-risk.

Amy Rylance, assistant director of health improvement at the charity, expressed optimism following Streeting's comments, noting the organization's commitment to evidence-based advocacy.

Rylance underscored the potential for targeted screening to significantly impact mortality rates among men predisposed to the disease.

The organization had submitted evidence to the National Screening Committee more than two years ago and is urging prompt action on this front.

As discussions continue, Prostate Cancer UK is calling for immediate steps from the government to facilitate proactive dialogues between GPs and at-risk patients regarding screening options.